EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nano-enabled colorectal cancer therapy

Qingqing Pan, Xi Fan, Li Xie, Di Wu, Rong Liu, Wenxia Gao, Kui Luo, Bin He, Yuji Pu

Journal of Controlled Release · 2023-10 · 362 · 548-564

DOI: 10.1016/j.jconrel.2023.09.014 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2023-10. Verfasst von Qingqing Pan und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Preclinical Medicine, Chengdu University, Chengdu 610106, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 145 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC), one of the most common and deadliest diseases worldwide, poses a great health threat and social burden. The clinical treatments of CRC encompassing surgery, chemotherapy, and radiotherapy are challenged with toxicity, therapy resistance, and recurrence. In the past two decades, targeted therapy and immunotherapy have greatly improved the therapeutic benefits of CRC patients but they still suffer from drug resistance and low response rates. Very recently, gut microbiota regulation has exhibited a great potential in preventing and treating CRC, as well as in modulating the efficacy and toxicity of chemotherapy and immunotherapy. In this review, we provide a cutting-edge summary of nanomedicine-based treatment in colorectal cancer, highlighting the recent progress of oral and systemic tumor-targeting and/or tumor-activatable drug delivery systems as well as novel therapeutic strategies against CRC, including nano-sensitizing immunotherapy, anti-inflammation, gut microbiota modulation therapy, etc. Finally, the recent endeavors to address therapy resistance, metastasis, and recurrence in CRC were discussed. We hope this review could offer insight into the design and development of nanomedicines for CRC and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsHumansImmunotherapyDrug Delivery Systems

Stichwörter der Autor:innen

Colorectal cancerGut microbiotaImmunotherapyNanoscale drug delivery systemsTherapy resistance

Autor:innen und Institutionen

  • School of Preclinical Medicine, Chengdu University, Chengdu 610106, China.
  • National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, China.
  • Meat Processing Key Laboratory of Sichuan Province, School of Food and Biological Engineering, Chengdu University, Chengdu 610106, China.
  • School of Preclinical Medicine, Chengdu University, Chengdu 610106, China. Electronic address: liurongscu@126.com.
  • College of Chemistry & Materials Engineering, Wenzhou University, Wenzhou 325027, China.
  • Huaxi MR Research Center (HMRRC), Department of Radiology, West China Hospital, Functional and molecular imaging Key Laboratory of Sichuan Province, Sichuan University, Chengdu 610041, China.

Zitieren

APA

Pan, Q., Fan, X., Xie, L., Wu, D., Liu, R., Gao, W., Luo, K., He, B., & Pu, Y. (2023). Nano-enabled colorectal cancer therapy. Journal of Controlled Release, 362, 548-564. https://doi.org/10.1016/j.jconrel.2023.09.014

Vancouver

Pan Q, Fan X, Xie L, Wu D, Liu R, Gao W, et al. Nano-enabled colorectal cancer therapy. Journal of Controlled Release. 2023;362:548-564. doi:10.1016/j.jconrel.2023.09.014

BibTeX
@article{Pan2023,
  author = {Pan, Qingqing and Fan, Xi and Xie, Li and Wu, Di and Liu, Rong and Gao, Wenxia and Luo, Kui and He, Bin and Pu, Yuji},
  title = {Nano-enabled colorectal cancer therapy},
  journal = {Journal of Controlled Release},
  year = {2023},
  volume = {362},
  pages = {548--564},
  doi = {10.1016/j.jconrel.2023.09.014}
}
Kostenlos starten →